American Heart Journal
Volume 152, Issue 1 , Pages 39-49, July 2006

Statin use in heart failure: A cause for concern?

  • Amresh Raina, MD
  • ,
  • Thomas Pickering, MD, DPhil
  • ,
  • Daichi Shimbo, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Daichi Shimbo, MD, Behavioral Cardiovascular Health and Hypertension Program, Columbia University Medical Center, 622 West 168th Street, PH 9-952, New York, NY 10032.

Behavioral Cardiovascular Health and Hypertension Program, Columbia University Medical Center, New York, NY

Received 5 July 2005; accepted 14 September 2005.

Background

Statins are effective in the prevention of coronary events and the treatment of acute coronary syndromes. However, their efficacy and safety in patients with heart failure (HF) are unknown. In this review, we discuss the evidence for the efficacy and safety of statin therapy in patients with HF.

Methods

We reviewed all original English-language, peer-reviewed journal articles published from 1985 to 2005 obtained from a search of the MEDLINE database. We focused on evidence for the efficacy and safety of statins based on data from patients with HF enrolled in major statin trials, analysis of the impact of statin use in patients with HF, and randomized clinical trials examining the effects of statins on cardiovascular outcomes in patients with HF.

Results

The major primary and secondary prevention statin trials largely excluded patients with HF. Statin use was also limited in randomized HF trials. Subgroup and retrospective analyses, and evidence from prospective cohort studies of statin use in patients with HF suggest statins improve cardiovascular prognosis in HF. The limited small randomized clinical trials also suggest statins improve symptoms, ejection fraction, and inflammatory biomarkers in patients with HF.

Conclusions

A growing weight of evidence suggests that statins have beneficial effects in HF. At this time, there is little evidence to support withdrawing or withholding statins from patients with HF. Ongoing randomized controlled trials that examine the efficacy of statin therapy in patients with HF should clarify the role of these agents in the context of HF.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The authors have no financial conflicts of interest.

 This work was supported by grants HL072866 and HL76857 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

PII: S0002-8703(05)00863-X

doi:10.1016/j.ahj.2005.09.008

American Heart Journal
Volume 152, Issue 1 , Pages 39-49, July 2006